Connect your AI

Lucid Diagnostics LUCD Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Castle BiosciencesCSTL

——

GRAIL, Inc.GRAL

——

Other financials

Income statement

Revenue$1.3M+51.7%

Gross profit-$369.0K+49.0%

Operating income-$12.1M+3.0%

Net income-$13.9M+48.3%

EPS (diluted)-$0.10+60.0%

Balance sheet

Cash & equivalents$27.9M+10.6%

Total debt$1.6M-35.1%

Total equity$4.0M+174%

Total assets$34.1M+3.9%

Cash flow

Operating cash flow-$12.1M+2.9%

CapEx$215.0K+131%

Free cash flow-$12.3M+1.9%

Valuation

Market cap$204.13M+58.5%

Enterprise value$177.85M+78.0%

P/S39.8×+10.2×

Profitability

Gross margin-66.8%—

Operating margin-959.6%-133pp

Net margin-876.7%-254pp

FCF margin-1,099.6%—

Returns & leverage

Return on equity-710.6%—

Debt / equity0.4×—

Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Lucid Diagnostics's proceeds from issuance of common stock relating to employee stock plans?: Lucid Diagnostics (LUCD) reported proceeds from issuance of common stock relating to employee stock plans of $210K in Q1 2026.
How has Lucid Diagnostics's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Lucid Diagnostics's proceeds from issuance of common stock relating to employee stock plans increased by 48.9% year-over-year, from $141K to $210K.